RxDoctor Payments Data

Ossama Rahman, MD

Interventional Cardiology · Florence, SCNPI 1972517860

Payments from drug & device makers

$7,511in general payments, 2019–2025

Across 89 payments — averaging $84.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Biotronik Inc.$2K
  • Medtronic$698
  • Boston Scientific$239
  • Shockwave Medical, Inc$201
  • AstraZeneca$193
  • plus $1K from 16 others

What the payments were for

  • Grants$2003%
  • Travel & lodging$4,84164%
  • Food & beverage$2,44333%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,511 in reported general payments places this provider in the 35th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$233,320
Medicare patients
1,546
Services billed
3,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$191,414
JardianceEmpagliflozin107$105,967
EntrestoSacubitril/Valsartan60$100,962
MultaqDronedarone Hcl20$41,195
BrilintaTicagrelor46$36,230
XareltoRivaroxaban40$28,560
Repatha SureclickEvolocumab28$26,298
FarxigaDapagliflozin Propanediol28$20,099
VerquvoVericiguat20$17,094
Ranolazine ErRanolazine76$3,452
Metoprolol Succinate258$2,383
ClopidogrelClopidogrel Bisulfate175$1,958
Atorvastatin Calcium197$1,901
Spironolactone226$1,602
Losartan Potassium160$1,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$20$105,967107 claims
NovartisEntresto$137$100,96260 claims
AstraZenecaBrilinta, Farxiga$193$56,32974 claims
Sanofi-aventis U.S. LLCMultaq$48$41,19520 claims
Johnson & JohnsonXarelto$117$28,56040 claims
MerckVerquvo$94$17,09420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →